Department of Education and Treatment of Obesity and Metabolic Disorders, University of Medical Sciences in Poznań, Szamarzewskiego Str. 84, 60-569 Poznań, Poland.
Department of Biochemistry and Human Nutrition, Pomeranian Medical University in Szczecin, Broniewskiego Str. 24, 71-460 Szczecin, Poland.
Nutrients. 2018 Jun 15;10(6):773. doi: 10.3390/nu10060773.
During the postmenopausal period, the risk of cardiovascular diseases is increased in many obese women and is associated with a worse cardiometabolic profile and a sub-chronic low-grade systemic inflammation caused by a gut barrier permeability dysfunction. Here, we tested whether administration of two different dosages of the multispecies probiotic Ecologic Barrier influenced the cardiometabolic biochemical parameters and lipopolysaccharide levels, the latter used as a marker of increased gut permeability in obese postmenopausal women. A total of 81 obese Caucasian postmenopausal women participated in the trial. The subjects were randomly assigned to three groups that received a placebo, a low dose (LD) (2.5 × 10⁸ colony forming units (CFU) per day), or a high dose (HD) (1 × 10 CFU per day) of lyophilisate powder containing live multispecies probiotic bacteria. The probiotic supplement was administered each day in two equal portions for 12 weeks. We found significant ( < 0.05) favorable changes (mostly large or medium effects) in the evaluated parameters in both the HD and LD groups but not in the placebo group. In the HD group, lipopolysaccharide, waist, fat mass, subcutaneous fat, uric acid, total cholesterol, triglycerides, low-density lipoprotein cholesterol, glucose, insulin, and insulin-resistant index (HOMA-IR) were improved. Similar changes were observed in the LD group, except for lipopolysaccharide, uric acid, triglycerides, and glucose levels. Additionally, significant differences were observed in both groups in terms of fat percentage and visceral fat. When the mean changes were compared between the three groups, statistically significant differences in lipopolysaccharide levels, uric acid, glucose, insulin, and HOMA-IR were found. Post hoc tests revealed significant differences in the mean changes (mostly medium effects) between the HD and LD groups for uric acid, glucose, insulin, and HOMA-IR. In the 12-week randomized, placebo-controlled, double-blind intervention, we observed that supplementation with the multispecies probiotic Ecologic Barrier favorably affected the risk factors in a dose-dependent manner, showing beneficial effects on the cardiometabolic parameters and gut permeability of the patients. Our results suggest that this product can be effective in the prevention and treatment of cardiovascular diseases in obese postmenopausal women.
在绝经后时期，许多肥胖女性患心血管疾病的风险增加，并且与较差的心脏代谢特征以及由肠道屏障通透性功能障碍引起的亚慢性低度全身炎症有关。在这里，我们测试了两种不同剂量的多菌种益生菌 Ecologic Barrier 是否会影响心脏代谢生化参数和内毒素水平，后者用作肥胖绝经后妇女肠道通透性增加的标志物。共有 81 名肥胖的白种绝经后妇女参加了试验。受试者被随机分配到三组，分别接受安慰剂、低剂量（LD）（每天 2.5 × 10⁸ 菌落形成单位（CFU））或高剂量（HD）（每天 1 × 10 CFU）冻干粉末形式的含有活多菌种益生菌的混合物。益生菌补充剂每天分两次服用，持续 12 周。我们发现，在 HD 组和 LD 组中，评估参数都有明显（<0.05）的有利变化（主要是大或中效应），而安慰剂组则没有。在 HD 组中，内毒素、腰围、脂肪量、皮下脂肪、尿酸、总胆固醇、甘油三酯、低密度脂蛋白胆固醇、血糖、胰岛素和胰岛素抵抗指数（HOMA-IR）都得到了改善。在 LD 组中观察到了类似的变化，但内毒素、尿酸、甘油三酯和血糖水平除外。此外，两组在脂肪百分比和内脏脂肪方面也有显著差异。当比较三组的平均变化时，发现内毒素水平、尿酸、葡萄糖、胰岛素和 HOMA-IR 存在统计学差异。事后检验显示，HD 组和 LD 组之间在尿酸、葡萄糖、胰岛素和 HOMA-IR 的平均变化（主要是中效应）方面存在显著差异。在 12 周的随机、安慰剂对照、双盲干预中，我们观察到多菌种益生菌 Ecologic Barrier 的补充以剂量依赖性方式有利地影响了风险因素，对患者的心脏代谢参数和肠道通透性产生了有益影响。我们的结果表明，该产品可有效预防和治疗肥胖绝经后女性的心血管疾病。
